tradingkey.logo

Trade shift could bring down costs for Brazil's Hypera

ReutersApr 24, 2025 3:28 PM

- A greater supply of raw materials and finished products in the global market due to the imposition of tariffs may represent an opportunity for long-term cost reduction for Hypera, CEO Breno de Oliveira said on Thursday.

Hypera is the largest publicly listed pharmaceutical company in Brazil.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI